The data are in – so will Gilead’s Trodelvy achieve its potential?
pharmaphorum
MARCH 8, 2022
In the study, Trodelvy (sacituzumab govitecan) met its objective of reducing progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment – including endocrine drugs, CDK4/6 inhibitors and two to four lines of chemotherapy.
52 
Let's personalize your content